HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected
article
OA: gold
CC0
⤵ 3 in-corpus citations
Abstract
OBJECTIVE: To analyze the utility of carbohydrate antigen (CA)125 and human epididymis protein 4 (HE4) to detect malignancy in women with ovarian endometriosis, when ovarian cancer is suspected and ultrasonography results are inconclusive. METHODS: Women who underwent surgery between 2015 and 2019 for ovarian endometriosis or for adnexal masses, with a final diagnosis of ovarian carcinoma (clear cell and endometrioid) were included in this retrospective study. The women were divided into three groups: ovarian endometriosis (OE), ovarian carcinoma without endometriosis (OC), and ovarian carcinoma with endometriosis (OC + E). Adnexal masses were assessed preoperatively by transvaginal ultrasonography according to the International Ovarian Tumor Analysis (IOTA) simple rules, and CA125 and HE4 blood levels were obtained. RESULTS: Of 208 women, 45 had malignancy, 16 in the OC + E group and 29 in the OC group. According to transvaginal ultrasonography, 13 were classified as undetermined risk of malignancy: OC group: 3, OE group: 3, and OC + E group: 7. When we compared the tumor biomarkers, significant differences in HE4 but not in CA125 levels were found between the groups. CONCLUSIONS: When ovarian malignancy is suspected in patients with ovarian endometriosis, HE4 is a more useful tumor biomarker to diagnose OC when ultrasonography results are inconclusive.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review via openalex
- Cancer Implications for Patients with Endometriosis via openalex
- Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125 via openalex
- Diagnostic performance of <scp>CA</scp> 125, <scp>HE</scp>4, and risk of Ovarian Malignancy Algorithm for ovarian cancer via openalex
- Evaluation of serum CA 125 levels in patients with pelvic pain related to endometriosis via openalex
- Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis via openalex
- Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. via openalex
- Relationship of Benign Gynecologic Diseases to Subsequent Risk of Ovarian and Uterine Tumors via openalex
- Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan via openalex
- W2131753057 via openalex
- W2137226085 via openalex
- W2059796825 via openalex
- W2153190986 via openalex
- W2309188630 via openalex
- W2326951125 via openalex
- W2342469666 via openalex
- W2400692327 via openalex
- W2478080461 via openalex
- W2040588648 via openalex
- W2599076725 via openalex
- W2015113538 via openalex
- W2889646458 via openalex
- W2945190152 via openalex
- W4210962013 via openalex
- W2063756481 via openalex
- W1716576701 via openalex
- W2124345906 via openalex
Cited by (3)
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:24:20.309598+00:00
License: CC0
· commercial use OK